Low-Dose Positron Emission Mammography Helps ID Breast Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Feb. 14, 2024 -- Low-dose positron emission mammography (PEM) is feasible for detecting invasive breast cancer, according to a study published online Feb. 9 in Radiology: Imaging Cancer.
Vivianne Freitas, M.D., from the University of Toronto, and colleagues examined the feasibility of low-dose PEM concurrent to magnetic resonance imaging (MRI) to identify breast cancer. Twenty-five female participants newly diagnosed with breast cancer underwent low-dose PEM with up to 185 MBq of fluorine 18-labeled fluorodeoxyglucose (18F-FDG). PEM images taken one and four hours following 18F-FDG injection were reviewed by two breast radiologists, unaware of the cancer location.
The researchers found that 24 of 25 cancers were identified with PEM from 100 sets of bilateral images; even after three hours of radiotracer uptake, performance was comparable. The median size of invasive cancer was 31 mm. At PEM, three additional in situ grade 2 lesions were missed. Compared with MRI, PEM detected fewer false-positive additional lesions, although the difference was not significant (16 versus 62 percent).
"While the full integration of this imaging method into clinical practice is yet to be confirmed, the preliminary findings of this research are promising, particularly in demonstrating the capability of detecting invasive breast cancer with low doses of fluorine-18-labeled FDG," Freitas said in a statement. "This marks a critical first step in its potential future implementation in clinical practice."
Several authors disclosed ties to Radialis Medical; one author holds a patent for organ-targeted solid-state tileable technology. Radialis Medical supplied equipment and assisted with maintenance.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
![](/img/logo/vendor/healthday-logo.png)
© 2024 HealthDay. All rights reserved.
Posted February 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.